Alejandro Pando

Dr. Alejandro Pando


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in World Neurosurgery
Verified
Journal Article
Closed access
APAlejandro Pando
Alejandro Pando
APAman M. Patel
Aman M. Patel
HCHannaan S. Choudhry
Hannaan S. Choudhry
JEJean Anderson Eloy
Jean Anderson Eloy
IGIra M. Goldstein
Ira M. Goldstein
JLJames K. Liu
James K. Liu

5 October 2022 in Gene
Verified
Journal Article
Closed access
APAlejandro Pando
Alejandro Pando
CSChristoph Schorl
Christoph Schorl
LFLoren D. Fast
Loren D. Fast
JRJohn L. Reagan
John L. Reagan

31 March 2023 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
APAlejandro Pando
Alejandro Pando
GHGabriel Hanna
Gabriel Hanna
IGIra Goldstein
Ira Goldstein

22 February 2023 in World Neurosurgery
Verified
Journal Article
Closed access
APAlejandro Pando
Alejandro Pando
CTChristopher E. Talbot
Christopher E. Talbot
DVDaniel J. Valdivia
Daniel J. Valdivia
JLJames K. Liu
James K. Liu

9 May 2025 in World Neurosurgery
Verified
Journal Article
Open access
APAlejandro Pando
Alejandro Pando
CHCaryn J. Ha
Caryn J. Ha
DTDrew Thibault
Drew Thibault
PKPriyank Khandelwal
Priyank Khandelwal
ANAnil Nair
Anil Nair
HSHai Sun
Hai Sun
Neuroendovascular interventions, including pipeline embolization device (PED)/flow diverter placement and coil embolization, are increasingly used in the management of nontraumatic subarachnoid hemorrhages (SAH). However, literature on trends, predictors of patient selection, and complications remains limited. This study aims to identify factors influencing treatment selection and risks associated with PED versus coil embolization in SAH. The 2016 to 2021 National Inpatient Sample was used to identify adult inpatients with a primary diagnosis of nontraumatic SAH. Univariate and multivariable analyses adjusting for demographics, comorbidity status, and hemorrhage etiology were used to characterize statistical associations. Of 62,567 patients identified as having an SAH from 2016 to 2021, 409 patients (0.65%) underwent PED, and 6834 patients (10.9%) underwent coil embolization. The remaining 88% underwent nonendovascular management. Complications associated with PED placement and not coil embolization included gastrointestinal (5.1% vs. 2.2%; P < 0.05) and respiratory tract bleeding (3.2% vs. 0.7%; P < 0.001). Those who underwent PED were less likely to have hydrocephalus (47.4% vs. 56.5%; P < 0.05) and receive external ventricular drain or ventriculoperitoneal shunt placement (38.9% vs. 48.4%; P < 0.01). After controlling for confounding factors, predictors for receiving coil embolization instead of PED placement included SAH originating from the anterior communicating artery (odds ratio [OR]: 4.0; 95% confidence interval [CI]: 2.87-5.90; P < 0.001), posterior communicating artery (OR: 2.0; CI: 1.90-3.63; P < 0.001), and middle cerebral artery (OR: 2.02; CI: 1.36-3.13; P < 0.05). PED is associated with a higher incidence of systemic hemorrhagic complications, particularly gastrointestinal and respiratory tract bleeding, compared to coil embolization. Patients undergoing PED require careful patient selection and postprocedural management.

19 January 2025 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
APAlejandro Pando
Alejandro Pando
RCRoger Cheng
Roger Cheng
CHCaryn J. Ha
Caryn J. Ha
GGGaurav Gupta
Gaurav Gupta
AAArevik Abramyan
Arevik Abramyan
KLKiwon Lee
Kiwon Lee
Introduction: Takotsubo Cardiomyopathy (TCM) is a rare but well recognized complication of subarachnoid hemorrhage associated with increased morbidity and poor clinical outcomes. There is a scarcity of literature describing the prevalence and risk factors associated with this complication. The aim of this study was to identify patients who are at risk of developing TCM in non-traumatic subarachnoid hemorrhage. Methods: The 2016 to 2021 National Inpatient Sample (NIS) was used to identify adult inpatients with a primary diagnosis of non-traumatic subarachnoid hemorrhage. Univariate and multivariable analyses adjusting for patient demographics, comorbidity status, and hemorrhage etiology were used to characterize statistical associations with disease-related complications. Patients with TCM were further divided into those with “good” or “poor” functional outcomes and compared. Results: A total of 42 141 patients were identified as having a subarachnoid hemorrhage from 2016 to 2021. Of these patients 486 patients (1.2%) were found to have TCM. TCM was associated with increased length of stay (19.15 ± 17.8 days vs 11.72 ± 14.4, P < .001), increased total costs ($451 502.59 ± 443 777.9 vs $242 327.92 ± 338 862.3, P < .001), increased number of days from admission to first procedure (1.74 ± 4.5 vs 1.94 ± 5.0, P < .001), and increased mortality (31.7% vs 22.8%, P < .001). After controlling for confounding factors, independent risk factors for TCM in patients with non-traumatic subarachnoid hemorrhage included: Female (Odds Ratio [OR]: 3.11, 95% Confidence Interval [CI]: 2.50-3.89, P < .001), Congestive Heart Failure (OR:4.60, CI:3.70-5.71, P < .001), and Fluid and Electrolyte Disorders (OR: 2.52, CI: 2.05-3.11, P < .001). Patients with good functional outcomes were found to have younger age (54.85 years ± 14.0 vs 58.14 ± 14.7, P < .001), decreased length of stay (17.11 ± 16.9 vs 19.83 ± 18.1, P < .001), decreased total charge ($370 245.94 ± 517 702.8 vs $477 366.55 ± 417 122.4, P < .001), and decreased mortality ( P < .001) compared to those with poor functional outcomes. Conclusion: TCM after subarachnoid hemorrhage is associated with increased mortality, length of stay, total cost, number of procedures in patients, and number of days to first procedure. Neurosurgeons and Neurocritical care medical professionals should be aware of the comorbidities and factors associated with increased TCM after subarachnoid hemorrhage in order to improve patient outcomes.